Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.

Antimicrobial agents and chemotherapy - 1 Feb 2012

Grau Thomas, Selchow Petra, Tigges Marcel, Burri Reto, Gitzinger Marc, Böttger Erik C, Fussenegger Martin, Sander Peter

Abstract excerpt

Ethionamide (ETH) is a second-line drug for the treatment of tuberculosis. As a prodrug, ETH has to be activated by EthA. ethA is controlled by its repressor EthR. 2-Phenylethyl-butyrate (2-PEB) inhibits EthR binding, enhances expression of EthA, and thereby enhances the growth-inhibitory effects of ethionamide, isoxyl, and thiacetazone in Mycobacterium tuberculosis strains with resistance to ETH due to inhA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Butyrates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple, Bacterial

Share to Drug Synergism

Share to Mycobacterium tuberculosis

Share to Oxidoreductases

Share to Oxygenases

Share to Phenylthiourea

Source

Open in PubMed Open full text

Identifiers

PMID: 22106218
DOI: 10.1128/AAC.05649-11
PMCID: PMC3264283

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.PMID 22106218Read ↗

Activation of the Pro-drug Ethionamide Is Regulated in MycobacteriaSemantic proximity Read ↗

An ethA-ethR-deficient Mycobacterium bovis BCG mutant displays increased adherence to mammalian cells and greater persistence in vivo, which correlate with altered mycolic acid composition.Semantic proximity Read ↗

The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosisSemantic proximity Read ↗

In silico structural analysis of EthA substitutions for ranking priority mutations leading to ethionamide resistance in <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

Molecular Investigation of Resistance to the Antituberculous Drug Ethionamide in Multidrug-Resistant Clinical Isolates of <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operatorSemantic proximity Read ↗

Heterologous Expression of ethA and katG in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis.Semantic proximity Read ↗

The new tuberculosis drug Perchlozone® shows cross-resistance with thiacetazone.Semantic proximity Read ↗

Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.Semantic proximity Read ↗

Perсhlozone Resistance in Clinical Isolates of Mycobacterium tuberculosisSemantic proximity Read ↗

Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis.Semantic proximity Read ↗

Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.